These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38275017)

  • 21. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study.
    Ezpeleta G; Navascués A; Viguria N; Herranz-Aguirre M; Juan Belloc SE; Gimeno Ballester J; Muruzábal JC; García-Cenoz M; Trobajo-Sanmartín C; Echeverria A; Martínez-Baz I; Vera-Punzano N; Casado I; López-Mendoza H; Ezpeleta C; Castilla J
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.
    Agüera M; Soler-Garcia A; Alejandre C; Moussalam-Merino S; Sala-Castellví P; Pons G; Penela-Sánchez D; González-Grado C; Alsina-Rosell J; Climent C; Esteva C; Fortuny C; de-Sevilla MF; García-García JJ; Brotons P; Balaguer A; Estrada J; Jordan I; Muñoz-Almagro C; Launes C
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14175. PubMed ID: 38899631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
    Mazagatos C; Mendioroz J; Rumayor MB; Gallardo García V; Álvarez Río V; Cebollada Gracia AD; Batalla Rebollo N; Barranco Boada MI; Pérez-Martínez O; Lameiras Azevedo AS; López González-Coviella N; Castrillejo D; Fernández Ibáñez A; Giménez Duran J; Ramírez Córcoles C; Ramos Marín V; Larrauri A; Monge S;
    Influenza Other Respir Viruses; 2024 May; 18(5):e13294. PubMed ID: 38716791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
    Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).
    Paes B; Mitchell I; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2703-11. PubMed ID: 22546928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
    Jorgensen SCJ
    J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015.
    Jepsen MT; Trebbien R; Emborg HD; Krause TG; Schønning K; Voldstedlund M; Nielsen J; Fischer TK
    Euro Surveill; 2018 Jan; 23(3):. PubMed ID: 29386093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
    Domachowske JB; Chang Y; Atanasova V; Cabañas F; Furuno K; Nguyen KA; Banu I; Kubiak RJ; Leach A; Mankad VS; Shroff M; Takas T; Villafana T; Wählby Hamrén U
    J Pediatric Infect Dis Soc; 2023 Aug; 12(8):477-480. PubMed ID: 37466917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.